Introduction
Tamoxifen (TAM) is the most commonly prescribed drug for the prevention and treatment of breast cancer (1, 2) . TAM is a non-steroidal anti-estrogen which acts, at least in part, by compete blockage of the estrogen receptor (ER) (3, 4) . However, the existence of an alternative mechanism of action for this drug is supported by the following clinical observations: i) 30% of patients with ER-negative cancer cells respond to TAM and ii) 30% of patients with ER-positive cancer cells are not sensitive to this anti-estrogen (5) . The ER activates transcription from classical hormone response elements, to which the ER binds directly and from various alternative response elements, to which the ER does not bind. ER action upon the ovalbumin proximal promoter and the collagenase and IGF-1 genes traces to activator of protein 1 (AP-1) sites that bind members of the Jun/Fos family of transcription factors (6, 7) . ER action upon the quinine reductase gene traces to an electrophile response element and these have been reported to bind ATF transcription factors, which are potential dimerization partners with Jun (8) . ER action upon the cyclin D gene is linked to a CRE-like element that also binds Jun/ATF (9) (10) (11) . ER also enhances the activity of promoters that are regulated by other factors.
Protein kinase C (PKC) was originally identified as a phospholipid-and calcium-dependent protein kinase (12) . PKC affects diverse cell functions through phosphorylation of target proteins. These cell functions involve a wide variety of fundamental physiological processes, including signal transduction, modulation of gene expression, proliferation and apoptosis (13) (14) (15) . Individual PKC isozymes exhibit various tissue distributions, subcellular localizations and biochemical properties, an indication that each member of the family plays specialized roles (14) , which ultimately translates into unique correlations with disease. The pAP-1(PMA)-TA-luc plasmid contains the AP-1 elements, which are designed to monitor the induction of the PKC signal transduction pathway. PKC is involved in various biochemical processes relevant to signal transduction pathways and linked to lipid signaling pathways (15) . By contrast, isoenzymes of PKC affect a number of biochemical processes, including cell growth, differentiation and transformation and plays a key role in signal transduction from multiple extracellular receptors (16, 17) . PKC activity is regulated by multiple activators and cofactors which associate via conserved domains within the enzyme structure (18) .
Inhibition of proliferation of estrogen receptor-positive MCF-7 human breast cancer cells by tamoxifen through c-Jun transcription factors
In the present study, TAM was observed to inhibit the growth of the human ER-positive breast cancer cell line, MCF-7 and ER-negative breast cancer cell line, MDA-MB-435, in a concentration-dependent manner. A previous study reported that the observed effects of TAM and its active metabolite on the proliferation of MDA-MB-435 cells were due to an ER-independent mechanism (5). To verify the role of c-Jun in TAM suppression of proliferation of the two breast cancer cell lines, the expression of c-Jun mRNA and protein levels were examined by reverse transcription polymerase chain reaction (RT-PCR) and western blot analysis. TAM treatment of MCF-7 cells activated the transcriptional activities of AP-1(PMA), which responds specifically to phorbol ester. Results indicate that TAM functions as an AP-1 activator to mediate cell functions. The inhibition rates of MCF-7 cells were found to correlate with c-Jun expression and stimulation of TAM, whereby TAM-stimulated MCF-7 cells were positively regulated by c-Jun overexpression and negatively regulated by c-Jun underexpression. To the best of our knowledge, this is the first study on the correlation between c-Jun and antiproliferation of TAM-stimulated MCF-7 cells.
Materials and methods
Cell culture. Human breast cancer cell lines, MCF-7 and MDA-MB-435, were obtained from Shanghai Cell Bank (Shanghai, China). Cells were cultured in Dulbecco's modified Eagle's medium (Gibco-BRL, Carlsbad, CA, USA) containing 10% fetal bovine serum in a humidified atmosphere with 5% CO 2 at 37˚C.
Cell proliferation assays. MCF-7 and MDA-MB-435 cells were plated at 1x10
4 cells/well in 96-well plates with six replicate wells, for 24 h in a humidified incubator (5% CO 2 at 37˚C). Cells were treated with various concentrations of TAM (The First Affiliated Hospital of Soochow University, Suzhou, China) for 48 h. Following this, 10 µl CCK-8 (Dojindo Laboratories, Kumamoto, Japan) solution was added to each well of the plate to measure cell proliferation. The plate was incubated for 4 h in the incubator. Optical density (OD) was measured at a wavelength of 450 nm using a microplate reader. Data were presented as the mean ± SD, which was derived from triplicate samples of at least three independent experiments. To examine the effect of c-Jun on inhibition rates of TAM-stimulated MCF-7 cells, cells were transfected with pIRES2-EGFP-c-Jun or pGPU6/GFP/Neo-c-Jun-shRNA using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). Cells were stimulated with TAM 48 h post-transfection.
Semiquantitative RT-PCR. Total RNA from TAM-treated or untreated MCF-7 and MDA-MB-435 cells was extracted by TRIzol (Gibco-BRL) according to the manufacturer's instructions. cDNA was generated from total RNA, using M-MLV RT (MBI; Fermentas, Waltham, MA, USA). Amplification was performed over 28 cycles consisting of 94˚C for 35 sec, 53˚C for 45 sec and 72˚C for 1 min. PCR products were separated by electrophoresis on a 1.5% agarose gel and stained with ethidium bromide to visualize the bands. To compare differences among samples, the relative intensity of each band was normalized against the intensity of the GAPDH band amplified from the same sample. The primer sequences for the genes and expected product sizes were as follows: 5'-TGAACGGGAAGCTC ACTGG-3' (sense) and 5'-TCCACCACCCTGTTGCTGTA-3 (antisense) for GAPDH (307 bp); 5'-GCCTCAGACAGTGCC CGAGAT-3' (sense) and 5'-GTTTAAGCTGTGCCACC TGTTCC-3' (antisense) for c-Jun (245 bp).
Western blot analysis. MCF-7 and MDA-MB-435 cells were harvested 48 h after TAM treatment and lysed with SDS sample buffer (80 mM Tris-HCl, 2% SDS, 300 mM NaCl and 1.6 mM EDTA). Cell extracts were separated using 10% SDS-PAGE gel electrophoresis, transferred onto nitrocellulose membrane and blocked with 5% skimmed milk. Following blocking, membranes were incubated with antibodies against GAPDH or c-Jun and then incubated with HRP-conjugated anti-mouse or -rabbit IgG antibodies. Protein bands were visualized with ECL solution. 
Results

Effect of TAM on the growth of MCF-7 and MDA-MB-435 cells in vitro.
To observe the proliferation inhibitory effects of TAM, MCF-7 and MDA-MB-435 cells were treated with various concentrations of TAM (0, 2.5, 5 and 10 µM) for 48 h and the rate of proliferation inhibition was detected by CCK-8 assay. As is evident in Fig. 1A and B, TAM was found to significantly inhibit the proliferation of MCF-7 and MDA-MB-435 cells. The effect of inhibition was enhanced with increased concentrations of TAM. Fig. 2A and B) .
Expression of c-Jun in MCF-
TAM activates AP-1(PMA)-mediated transcriptional activation in MCF-7 cells.
TAM is thought to function primarily by competitive blockage of the ER. In this study, the Dual-Luciferase reporter assay system was utilized to investigate the role of TAM on signaling pathways, including AP-1(PMA) and AP-1. The plasmid pAP-1(PMA)-Luc and pAP-1-Luc were transfected into MCF-7 and MDA-MB-435 cells, which encode luciferase controlled by AP-1(PMA) and AP-1 elements, respectively. Relative luciferase activity was normalized by co-transfection with pRL-SV40. Cells were stimulated with various concentrations of TAM 36 h post-transfection. In MCF-7 cells, TAM enhanced AP-1(PMA)-luciferase activity by ~200% (Fig. 3A) . In addition, TAM was identified to induce dose-dependent activation of the AP-1(PMA) reporter gene. However, TAM had a limited effect on AP-1. In MDA-MB-435 cells, TAM had almost no effect on AP-1(PMA) and AP-1 (Fig. 3B) .
Inhibition of proliferation of MCF-7 cells by TAM through c-Jun.
To investigate a role for c-Jun in inhibition of TAM-stimulated MCF-7 cell growth, c-Jun vectors with upregulated or downregulated expression of c-Jun in cells were utilized. MCF-7 cells were transfected with pIRES2-EGFP-c-Jun or pGPU6/GFP/Neo-c-Jun-shRNA and stimulated with TAM 48 h post-transfection. CCK-8 was used to measure cell proliferation. Inhibition rates of TAM-stimulated MCF-7 cells were found to be positively and negatively regulated by overexpression and underexpression of c-Jun, respectively ( Fig. 4A and B) . These results indicate that c-Jun mediates antiproliferation signals in TAM-stimulated MCF-7 cells and TAM-effected c-Jun may also induce a protein with antiproliferative effects. Antiestrogenic drugs, including TAM, provide an effective therapeutic agent for females with hormone-dependent cancer in neoadjuvant, adjuvant and advanced disease settings (19) . However, the existence of an alternative mechanism of action for this drug is supported by a number of clinical observations. For example, 30% of patients with ER-negative cancer cells respond to TAM and 30% of patients with ER-positive cancer cells are not sensitive to this anti-estrogen (5). Therefore, the uses of TAM are limited. Long-term exposure to TAM is associated with resistance and, in specific cases, with tumor growth stimulation (20, 21) . The signaling pathways by which breast tumors acquire the ability to grow in the presence of antiestrogens, including TAM, remain poorly understood. One of the mechanisms by which cell lines develop resistance to antiestrogens is through the utilization of alternative signaling pathways that support cell growth in the presence of antiestrogens. Several signalling molecules, including PKC-δ, are known to play a major role in E2-mediated signaling (22, 23) .
The PKC family of serine/threonine kinases has been intensively studied in cancer since their identification as major receptors for the tumor-promoting phorbol esters. The contribution of each individual PKC isozyme to malignant transformation is only partially understood, but it is clear that each PKC plays a different role in cancer progression. PKC deregulation is a common phenomenon observed in breast cancer and PKC expression and localization are usually dynamically regulated during mammary gland differentiation and involution. Overexpression of several PKCs has been reported in malignant breast tissue and breast cancer cell lines (24) . Since PKC deregulation is observed in breast cancer (25) , this kinase family is a promising target for blocking or reverting breast cancer malignancy. PKC is known to have at least 10 phospholipid-dependent serine-threonine kinase isoforms, one of which is PKCδ. The role of PKCδ in breast cancer remains ambiguous and limited information is available with regard to expression levels of PKCδ in primary tumors. Although altered PKCδ expression does not appear to be a prerequisite for breast cancer progression, specific previous studies, including our own, have identified a protumorigenic role for PKCδ overexpression in murine mammary cells via the induction of survival and anchorage-independent growth (26) . PKCδ has been reported to promote proliferation (27) and metastasis development (28) , whereas its depletion is sufficient to drive murine mammary cancer cells into apoptosis (29) . By contrast, several studies have revealed that PKCδ mediates antiproliferative responses. For example, the antimitogenic effect of inositol hexaphosphate in MCF-7 human breast cancer cells, which involves inhibition of ERK and Akt as well as pRb hypophosphorylation, is mediated by PKCδ (30) . Crosstalk between PKCδ and ER has also been hypothesized. Of note, ER-positive breast cancer cell lines express high levels of PKCδ and are associated with an improved endocrine response, whereas ER-negative breast cancer cell lines express low PKCδ levels (31) . Moreover, PKCδ is likely to play a crucial role in antiestrogen resistance in breast cancer cells and has been associated with acquired resistance to TAM in patients with breast cancer (32) . Based on these studies, we hypothesize that the PKC pathway is one of the most important pathways associated with inhibition of MCF-7 cell proliferation by TAM. To investigate this hypothesis, the signal transduction reporter vector was analyzed in MCF-7 cells stimulated by TAM.
pAP-1(PMA)-TA-luc is a signal transduction reporter vector. The vector contains multiple copies of the AP-1 enhancer, located upstream of luciferase, that responds specifically to phorbol ester treatment. Activating the PKC pathway by adding phorbol esters, including PMA, results in transcription factors binding AP-1 elements on the vector. It is designed for monitoring the induction of the PKC signal transduction pathway. AP-1 is a heterodimeric transcription factor that is composed of various members of the Jun and Fos families and binds to DNA at specific AP-1 binding sites. AP-1 transcriptional activity is increased by phosphorylation at serine residues in the c-Jun component of AP-1. In this study, no significant difference in c-Jun transcript and protein levels was identified in MCF-7 and MDA-MB-435 cells stimulated by TAM for 48 h. In addition, transcriptional reporter gene assays indicated that TAM is an AP-1(PMA)-associated activator (Fig. 3A) . These data indicate that TAM may function in a similar manner to PMA to modulate c-Jun activity through the PKC pathway in MCF-7 cells. To determine the role of c-Jun in antiproliferation of MCF-7 cells stimulated by TAM, the correlation between inhibition rates of MCF-7 cells and c-Jun expression and stimulation of TAM was analyzed. Inhibition rates of TAM-stimulated MCF-7 cells were revealed to be positively regulated by c-Jun overexpression and negatively regulated by c-Jun underexpression.
Overall, these results indicate that TAM inhibits proliferation of MCF-7 and MDA-MB-435 cells and has no statistically significant effect on c-Jun transcript and protein levels. However, TAM-stimulated antiproliferation of MCF-7 cells is positively regulated by c-Jun through activation of the PKC pathway.
